Strategic Acquisition WCCT Global is now part of Altasciences, signaling a consolidated early-phase drug development capability. This presents a sales opportunity to offer integrated CRO and CDMO services to clients seeking streamlined, end-to-end early-phase programs under one umbrella.

Expanded Capabilities Altasciences’ growth through partnerships and in-house manufacturing supports a broader service suite, enabling cross-sell of early-phase clinical development with formulation and small molecule dosage form capabilities to similar biotech and pharma sponsors.

North American Footprint With multiple North American locations and a transition to a unified brand, there is potential to target sponsors looking for convenient, locally resourced early-phase programs, optimization of timelines, and regional regulatory familiarity.

Tech-Enabled Efficiency Adoption of platforms like Power Platform, Veeva, and other digital tools indicates a modernization push. This suggests openness to additional tech-enabled services such as data analytics, e-consent, eTMF optimization, and model-informed decision support collaborations.

Sustainability & ESG EcoVadis partnership and sustainability focus create an angle for clients prioritizing ESG-aligned vendors, offering shared value in responsible sourcing, waste reduction, and sustainable clinical operations as part of the supplier selection criteria.